论文部分内容阅读
目的:探讨应用普米克令舒联合博利康尼令舒治疗成人哮喘急性发作的临床疗效及安全性。方法:选取2011年1月至2011年6月间我院收治的成人支气管哮喘急性发作期患者72例作为研究对象,将其随机分为甲组(38例)和乙组(34例)。对两组患者应用相同的基础药物进行常规治疗,在为甲组患者应用常规药物治疗的基础上加用普米克令舒联合博利康尼令舒进行治疗。将两组患者的血气指标进行记录和评价,并将所得结果及两组患者的临床资料进行回顾性的分析。结果:治疗7天后,将两组患者治疗前后的血气指标进行对比。结果显示,两组患者治疗后的血气指标均明显优于治疗前。甲组患者的临床疗效明显优于乙组患者,差异显著,具有统计学意义。甲组患者在症状缓解时间、机械通气使用率、激素用量、后期临床控制等方面均明显好于乙组患者,差异显著,具有统计学意义。在甲组患者中无发生不良反应的患者。结论:应用普米克令舒联合博利康尼令舒治疗成人哮喘急性发作的临床效果显著。此疗法可使该病患者的血气指标在短时间内趋于正常,且副作用及不良反应发生率几乎为零,证明此疗法具有极高的安全性,值得在临床上推广应用。
Objective: To investigate the clinical efficacy and safety of pulmicort and combiblocinolide in treating acute exacerbation of adult asthma. Methods: Seventy-two patients with acute exacerbation of adult bronchial asthma admitted to our hospital from January 2011 to June 2011 were selected as study subjects and randomly divided into group A (38 cases) and group B (34 cases). The two groups of patients with the same basic drugs for routine treatment, in patients with Group A conventional treatment based on the application of Pulmicort Respubliquone with comorbidazole treatment. The blood gas indexes of two groups of patients were recorded and evaluated, and the results and the clinical data of two groups were retrospectively analyzed. Results: After 7 days of treatment, the blood gas indexes before and after treatment of the two groups were compared. The results showed that the two groups of patients after treatment, blood gas indicators were significantly better than before treatment. The clinical efficacy of patients in group A was significantly better than that in patients in group B, with significant differences, with statistical significance. Patients in group A were significantly better than those in group B in terms of symptom relief, mechanical ventilation utilization, hormone dosage, and late clinical control. The difference was significant and statistically significant. In group A patients without adverse reactions in patients. Conclusion: The clinical effect of pulmicort and combiblocin in the treatment of acute exacerbation of adult asthma is remarkable. This therapy can make the patient’s blood gas index in a short period of time tends to be normal, and the incidence of side effects and adverse reactions is almost zero, proving the high safety of this therapy, it is worth to promote the clinical application.